- Home
- KALU vs VRDN Comparison
KALU vs VRDN Comparison
Compare KALU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALU | VRDN |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KALU | VRDN |
|---|---|---|
| Price | $159.30 | $19.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $147.33 | $35.46 |
| AVG Volume (30 Days) | 240.9K | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 9.43 | N/A |
| Revenue | ★ $1,585,900,000.00 | $5,706,000.00 |
| Revenue This Year | $13.37 | $13.73 |
| Revenue Next Year | $2.62 | $279.00 |
| P/E Ratio | $16.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $71.44 | $13.18 |
| 52 Week High | $195.96 | $34.29 |
Technical Indicators
Market Signals| Indicator | KALU | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 56.00 |
| Support Level | $156.33 | $17.54 |
| Resistance Level | $183.99 | $20.00 |
| Average True Range (ATR) | 7.56 | 0.75 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 34.66 | 75.00 |
Price Performance
Historical ComparisonAbout KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.